



TRANSMITTAL FORM

(To be used for all correspondence
after initial filing)

Application Number	10/820,983
Filing Date	April 8, 2004
First Named Inventor	Lawrence Steinman
Art Unit	1653
Examiner Name	
Attorney Docket No.	690068.412C4

ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form
- ☐ Fee Attached
- ☐ Amendment/Response
 - ☐ After Final
 - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement; Form PTO-1449
- ☐ Cited References
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts under 37 C.F.R. 1.52 or 1.53
- ☐ Response to Missing Parts/Incomplete Application

- ☐ Drawing(s)
- ☐ Request for Corrected Filing Receipt
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation, Change of Correspondence Address
- ☐ Declaration
- ☐ Statement under 37 CFR 3.73(b)
- ☐ Terminal Disclaimer
- ☐ Request for Refund

- ☐ CD(s), Number of CD(s) _____
- ☐ After Allowance Communication to Technology Center (TC)
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to TC (*Appeal Notice, Brief, Reply Brief*)
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Return Receipt Postcard
- ☐ Additional Enclosure(s) (*please identify below*):

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	William T. Christiansen, Ph.D.	Customer Number 00500
Signature		
Date	7/6/04	

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Jason Anover	
Signature		Date: 7/6/04

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 422 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. 495768



PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

July 6, 2004
Date

Jason Añover

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Lawrence Steinman et al.
Application No. : 10/820,983
Filed : April 8, 2004
For : METHODS FOR TREATMENT OF MULTIPLE
SCLEROSIS USING PEPTIDE ANALOGUES AT
POSITION 91 OF HUMAN MYELIN BASIC PROTEIN

Art Unit : 1653
Docket No. : 690068.412C4
Date : July 6, 2004

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Form PTO-1449. This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior Application No. 10/270,707, filed October 11, 2002, now U.S. Patent 6,740,638, which is a continuation of prior Application No. 09/989,476, filed November 19, 2001, now U.S. Patent 6,489,299, which is a continuation of prior Application No. 08/953,937, filed October 20, 1997, now U.S. Patent 6,369,033, which is a continuation of prior Application No. 08/342,078, filed November 18, 1994, now abandoned. The references listed on the attached Form PTO-1449

were submitted to and/or cited by the Patent and Trademark Office in these prior applications and, therefore, are not required to be provided in this application. If the Examiner wishes, copies will be provided upon request. As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



William T. Christiansen, Ph.D.

Registration No. 44,614

Enclosures:

Postcard

Form PTO-1449

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

495770

FORM PTO-1449
(REV. 7-80)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

690068.412C4

APPLICATION NO.

10/820,983

APPLICANTS

Lawrence Steinman et al.

FILING DATE

April 8, 2004

GROUP ART UNIT

1653

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,468,481	11/21/95	Sharma et al.	530	402	
	AB	5,858,980	01/ /99	Weiner et al.	514	13	
	AC	6,329,499	12/ /01	Ling et al.	530	327	
	AD	6,369,033	04/09/02	Steinman et al.	514	14	
	AE	6,489,299	12/03/02	Steinman et al.	514	14	
	AF	6,740,638	05/25/04	Steinman et al.	514	14	
	AG						
	AH						
	AI						
	AJ						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK	WO 91/12816	09/05/91	WIPO		
	AL	WO 92/21367	12/10/92	WIPO		
	AM	WO 93/08212	04/29/93	WIPO		
	AN	WO 93/21222	10/28/93	WIPO		
	AO	WO 95/08572	03/30/95	WIPO		

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AP	Abstract 65027 from Biol. Abstr. 81(7): AB-701 (1985) of the article "Monoclonal antibodies to human myelin basic protein," by Chou et al., J. Neurochem. 46(1): 47-53, 1985.
	AQ	Acha-Orbea et al., "Limited Heterogeneity of T Cell Receptors from Lymphocytes Mediating Autoimmune Encephalomyelitis Allows Specific Immune Intervention," Cell 54: 263-273, 1988.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 690068.412C4	APPLICATION NO. 10/820,983
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Lawrence Steinman et al.	
		FILING DATE April 8, 2004	GROUP ART UNIT 1653

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BD					
	BE					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	F	Babbitt et al., "Antigenic competition at the level of peptide-Ia binding," Proc. Natl. Acad. Sci. USA 83: 4509-4513, 1986.
	BG	Bernard C., "Experimental Autoimmune Encephalomyelitis in Mice: Genetic Control of Susceptibility," Journal of Immunogenetics 3: 263-274, 1976.
	BH	Brocke et al., "In Vitro Proliferative Responses and Antibody Titers Specific to Human Acetylcholine Receptor Synthetic Peptides in Patients with Myasthenia Gravis and Relation to HLA Class II Genes," J. Clin. Invest. 81: 1894-1900, 1988.
	BI	Brostoff and Howell, "T Cell Receptors, Immunoregulation, and Autoimmunity," Clinical Immunology and Immunopathology 62(1): 1-7, 1992.
	BJ	Carter and Rodriguez, "Immunosuppressive Treatment of Multiple Sclerosis," Mayo Clin. Proc. 64: 664-669, 1989.
	BK	Chou et al., "Identity of Myelin Basic Protein from Multiple Sclerosis and Human Control Brains: Discovery of a Genetic Variant," Journal of Neurochemistry 30: 745-750, 1978.
	BL	Chou et al., "Monoclonal antibodies to human myelin basic protein," Abstract 65027 from Biol. Abstr. 81(7): AB-701, found in J. Neurochem. 46(1): 47-53, 1985.
	BM	Cover of Journal of Immunology, vol. 153, No. 4, issued Aug. 15, 1994 (date-stamped Aug. 11, 1994)
	BN	Day et al., "The Polyclonal Antibody Response of Lewis Rats to the Synthetic Encephalitogenic Neuropeptide S55S (Residues 72-84 of Guinea Pig Myelin Basic Protein) and Its Analogs," Journal of Neuroscience Research 18: 214-221, 1987.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 690068.412C4		APPLICATION NO. 10/820,983	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Lawrence Steinman et al.			
				FILING DATE April 8, 2004		GROUP ART UNIT 1653	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA						
	CB						
	CC						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
	CD						
	CE						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	CF	Day et al., "The Polyclonal Antibody Responses of Lewis Rats to the Synthetic Encephalitogenic Neuropeptide S55S (Residues 72-84 of Guinea Pig Myelin Basic Protein) and Its Analogs," Journal of Neuroscience Research 18: 214-221, 1987.					
	CG	Einstein et al., "Suppression of Experimental Allergic Encephalomyelitis By Chemically Modified Encephalitogen," Immunochemistry 9: 1013-1019, 1972.					
	CH	Evavold and Allen, "Separation of IL-4 Production from Th Cell Proliferation by an Altered T Cell Receptor Ligand," Science 252: 1308-1310, 1991.					
	CI	Gammon et al., "Neonatal T-cell tolerance to minimal immunogenic peptides is caused by clonal inactivation," Nature 319: 413-415, 1986.					
	CJ	Gaur et al., "Amelioration of Autoimmune Encephalomyelitis by Myelin Basic Protein Synthetic Peptide-Induced Anergy," Science 258: 1491-1494, 1992.					
	CK	Gautam et al., "A Polyalanine Peptide With only Five Native Myelin Basic Protein Residues Induces Autoimmune Encephalomyelitis," J. Exp. Med. 176: 605-609, 1992.					
	CL	Gautam et al., "Inhibition of Experimental Autoimmune Encephalomyelitis By a Nonimmunogenic Non-Self Peptide That Binds to I-A.sup.u," Journal of Immunology 148(10): 3049-3054, 1992.					
	CM	Hadden et al., "Thymic Hormones, Interleukins, Endotoxin and Thymomimetic Drugs in T Lymphocyte Ontogeny," in Advances in Immunopharmacology 3, L. Chedid et al. (Eds.), 1985, pp. 487-497.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 690068.412C4		APPLICATION NO. 10/820,983	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Lawrence Steinman et al.			
				FILING DATE April 8, 2004		GROUP ART UNIT 1653	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	DA						
	DB						
	DC						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	DE						
	DF						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	DG	Hashim and Day, "Synthetic Peptide Analogs to Probe the Immunological Expression of the Rat Encephalitogenic Neuropeptide," Journal of Neuroscience Research 18: 209-213, 1987.					
	DH	Hashim et al., "Suppression and Reversal of Allergic Encephalomyelitis in Guinea Pigs with a Non-Encephalitogenic analogue of the Tryptophan Region of the Myelin Basic Protein," Journal of Immunology 116(1): 126-130, 1976.					
	DI	Hashim, G., "Experimental Allergic Encephalomyelitis: Activation of Suppressor T Lymphocytes By a Modified Sequence of the T Effector Determinant," Journal of Immunology 126(2): 419-423, 1981.					
	DJ	Jahnke et al., "Sequence Homology Between Certain Viral Proteins and Proteins Related to Encephalomyelitis and Neuritis," Science 229: 282-284, 1985.					
	DK	Kardys and Hashim, "Experimental Allergic Encephalomyelitis in Lewis Rats: Immunoregulation of Disease By a Single Amino Acid Substitution in the Disease-Inducing Determinant," Journal of Immunology 127(3): 862-866, 1981.					
	DL	Karin et al., "Reversal of Experimental Autoimmune Encephalomyelitis by a Soluble Peptide Variant of a Myelin Basic Protein Epitope: T Cell Receptor Antagonism and Reduction of Interferon .gamma. and Tumor Necrosis Factor .alpha. Production," J. Exp. Med. 180: 2227-2237, 1994.					
	DM	Kira et al., "Experimental Allergic Encephalomyelitis in Rabbits. A Major Encephalitogenic Determinant within Residues 1-44 of Myelin Basic Protein," J. of Neuroimmunol. 12(3): 183-193, 1986.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 690068.412C4	APPLICATION NO. 10/820,983
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Lawrence Steinman et al.	
		FILING DATE April 8, 2004	GROUP ART UNIT 1653

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	EA						
	EB						
	EC						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	ED					
	EE					

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	EF	Kuchroo et al., "A Single TCR Antagonist Peptide Inhibits Experimental Allergic Encephalomyelitis Mediated by a Diverse T Cell Repertoire," Journal of Immunology 153:3326-3336, 1994.
	EG	Lamont et al., "Inhibition of Experimental Autoimmune Encephalomyelitis Induction In SJL/J Mice By Using A Peptide With High Affinity For IA.sup.s Molecules," Journal of Immunology 145(6): 1687-1693, 1990.
	EH	Lehninger, A., "The Amino Acid Building Blocks of Proteins," in Biochemistry, 2nd ed., Worth Publishers, Inc. pp. 71-75, 1975.
	EI	Martin et al. Diversity in Fine Specificity and T Cell Receptor . . . J. Immunology, vol. 148, No. 5, pp. 1359-1366, 1992
	EJ	Martin et al., "A Myelin Basic Protein Peptide Is Recognized by Cytotoxic T Cells in the Context of Four HLA-DR Types Associated with Multiple Sclerosis," Journal of Experimental Medicine 173: 19-24, 1991.
	EK	Martin et al., "Diversity of Fine Specificity and T Cell Receptor Usage of the Human CD4.sup.30 Cytotoxic T Cell Response Specific for the Immunodominant Myelin Basic Protein Peptide 87-106," Journal of Immunology 148(5): 1359-1366, 1992.
	EL	Martin et al., "Immunological Aspects of Demyelinating Diseases," Annu. Rev. Immunol. 10: 153-87, 1992.
	EM	Rothbard and Taylor, "A sequence pattern common to T cell epitopes," EMBO J. 7(1): 93-100, 1988.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 690068.412C4		APPLICATION NO. 10/820,983	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Lawrence Steinman et al.			
				FILING DATE April 8, 2004		GROUP ART UNIT 1653	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	FA						
	FB						
	FC						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	FD						
	FE						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	FF	Rothbard, J., "Peptides and the Cellular Immune Response," Ann. Inst. Pasteur/Virologie 137 E: 518-526, 1986.					
	FG	Rudinger, J., "Characteristics of the amino acids as components of a peptide hormone sequence," in Peptide Hormones, J. A. Parsons (ed.), University Park Press, Baltimore, pp. 1-7, 1976.					
	FH	Sakai et al., "Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins," Proc. Natl. Acad. Sci. USA 86: 9470-9474, 1989.					
	FI	Servis et al., "Two adjacent epitopes on a synthetic dodecapeptide induce lactate dehydrogenase B-specific helper and suppressor T cells," Proc. R. Soc. Lond. B 228: 461-470, 1986.					
	FJ	Sette et al., "Analysis of lysozyme-specific immune responses by synthetic peptides. I. Characterization of antibody and T cell-mediated responses to the N-terminal peptide of hen egg-white lysozyme," Eur. J. Immunol. 16: 1-6, 1986.					
	FK	Smilek et al., "A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis," Proc. Natl. Acad. Sci. USA 88: 9633-9637, 1991.					
	FL	Sriram et al., "Administration of Myelin Basic Protein-Coupled Spleen Cells Prevents Experimental Allergic Encephalitis," Cellular Immunology 75: 378-382, 1983.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 690068.412C4		APPLICATION NO. 10/820,983	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Lawrence Steinman et al.			
				FILING DATE April 8, 2004		GROUP ART UNIT 1653	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	GA						
	GB						
	GC						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	GD						
	GE						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	GF	Steinman et al., "Natural occurrence of thymocytes that react with myelin basic protein," Neurology 30(7): 755-759, 1980.					
	GG	Steinman et al., "Regulation of autosensitisation to encephalitogenic myelin basic protein by macrophage-associated and soluble antigen," Nature 265: 173-175, 1977.					
	GH	Steinman et al., "The Epigenetics Of Multiple Sclerosis: Clues to Etiology and a Rationale for Immune Therapy," Annu. Rev. Neurosci. 17: 247-65, 1994.					
	GI	Su et al., "Synthetic Myelin Basic Protein Peptide Analogs Are Specific Inhibitors of Phospholipid/Calcium-Dependent Protein Kinase (Protein Kinase C)," Biochemical and Biophysical Research Communications 134(1): 78-84, 1986.					
	GJ	Talmadge et al., "Screening Models for Biological Response Modifiers," in 13th International Congress of Chemotherapy. Symposium, Biological Response Modifiers; SY 64 part 203, Vienna Aug. 28-Sep. 2, 1993, pp. 203/19-203/34.					
	GK	Teitelbaum et al., "Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1," Proc. Natl. Acad. Sci. USA 85: 9724-9728, 1988.					
	GL	Vogt et al. Ligand Motifs of HLA-DRB5*0101 . . . J. Immunology. vol. 153, pp. 1665-1673, 1994.					
	GM	Vogt et al., "Ligand Motifs of HLA-DRB5*0101 and DRB1*1501 Molecules Delineated from Self-Peptides," Journal of Immunology 153: 1665-1673, 1994.					
	GN	Wraith et al., "Antigen Recognition in Autoimmune Encephalomyelitis and the Potential for Peptide-Mediated Immunotherapy," Cell 59: 247-255, 1989.					
EXAMINER				DATE CONSIDERED			
<p>* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).</p>							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 690068.412C4		APPLICATION NO. 10/820,983	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Lawrence Steinman et al.			
				FILING DATE April 8, 2004		GROUP ART UNIT 1653	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	HA						
	HB						
FOREIGN PATENT DOCUMENTS							
	HC	DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION YES NO	
	HD						
	HE						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	HF	Wraith et al., "T Cell Recognition as the Target for Immune Intervention in Autoimmune Disease," Cell 57: 709-715, 1989.					
	HG	Wucherpennig et al. Structure Requirements for Binding of an . . . J. Exp. Med. vol. 179, pp. 279-290, 1994.					
	HH	Wucherpennig et al., "Structural Requirements for Binding of an Immunodominant Myelin Basic Protein Peptide to DR2 Isotypes and for Its Recognition by Human T Cell Clones," J. Exp. Med. 179: 279-290, 1994.					
	HI	Zamvil and Steinman, "The T Lymphocyte in Experimental Allergic Encephalomyelitis," Annu. Rev. Immunol. 8: 579-621, 1990.					
	HJ	Zamvil et al., "Encephalitogenic T Cell Clones Specific for Myelin Basic Protein," J. Exp. Med. 162: 2107-2124, 1985.					
	HK	Zamvil et al., "Multiple Discrete Encephalitogenic Epitopes of the Autoantigen Myelin Basic Protein Include a Determinant for I-E Class II-Restricted T Cells," J. Exp. Med. 168: 1181-1186, 1988.					
	HL	Zamvil et al., "T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination," Nature 317: 355-358, 1985.					
	HM	Zamvil et al., "T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis," Nature 324: 258-260, 1986.					
	HN	Zamvil, S., "T-Cell Specificity for Class II(I-A) and the Encephalitogenic N-Terminal Epitope of the Autoantigen Myelin Basic Protein," Journal of Immunology 139(4): 1075-1079, 1987.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							